ACE2 activation by xanthenone prevents leptin-induced increases in blood pressure and proteinuria during pregnancy in Sprague-Dawley rats

Reproductive Toxicology

Volumn 49, Issue , 2014, Pages 155-161

  Ibrahim, Hisham Saleh ^a   Froemming, Gabrielle Ruth Anisah ^b   Omar, Effat ^b   Singh, Harbindar Jeet ^b  

^a UNIVERSITI SULTAN ZAINAL ABIDIN   (Malaysia)

^b UNIVERSITI TEKNOLOGI MARA   (Malaysia)

Author keywords

ACE2; Blood pressure; E selectin; Endothelial activation; Endothelin 1; ICAM 1; Leptin; Proteinuria

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIN 1; INTERCELLULAR ADHESION MOLECULE 1; LEPTIN; UNCLASSIFIED DRUG; XANTHENE DERIVATIVE; XANTHENONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; HOUSEKEEPING GENE; HYPERTENSION; KIDNEY; NONHUMAN; PREGNANCY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN URINE LEVEL; PROTEINURIA; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION; ANIMAL; BLOOD; BLOOD PRESSURE; CHEMICALLY INDUCED; COMPLICATION; DRUG EFFECTS; METABOLISM; PREGNANCY COMPLICATIONS; SPRAGUE DAWLEY RAT;

ANIMALS; BLOOD PRESSURE; E-SELECTIN; ENDOTHELIN-1; ENZYME ACTIVATION; FEMALE; INTERCELLULAR ADHESION MOLECULE-1; LEPTIN; PEPTIDYL-DIPEPTIDASE A; PREGNANCY; PREGNANCY COMPLICATIONS; PROTEINURIA; RATS; RATS, SPRAGUE-DAWLEY; XANTHENES;

EID: 84907553885     PISSN: 08906238     EISSN: 18731708     Source Type: Journal    
DOI: 10.1016/j.reprotox.2014.08.006     Document Type: Article

References (68)

1. Thadhani R., Stampfer M.J., Hunter D.J., Manson J.E., Solomon C.G., Curhan G.C. High body mass index and hypercholesterolemia: risk of hypertensive disorders of pregnancy. Obstetr Gynecol 1999, 94(4):543.
2. Igel M., Becker W., Herberg L., Joost H.G. Hyperleptinemia, leptin resistance, and polymorphic leptin receptor in the New Zealand obese mouse. Endocrinology 1997, 138(10):4234.
3. Teppa R.J., Ness R.B., Crombleholme W.R., Roberts J.M. Free leptin is increased in normal pregnancy and further increased in preeclampsia* 1. Metabolism 2000, 49(8):1043-1048.
4. Iftikhar U., Khoja A., Mehjabeen A.I., Karira K.A. Evaluation of serum leptin levels during normal pregnancy and in pre-eclampsia. J Ayub Med Coll Abbottabad 2008, 20(4):137-140.
5. Miehle K., Stepan H., Fasshauer M. Leptin, adiponectin, and other adipokines in gestational diabetes mellitus and preeclampsia. Clin Endocrinol 2011.
6. Singh H.J., Abu Bakar A., Che Romli A., Nila A. Raised leptin concentrations in feto-placental tissues from women with preeclampsia. Hypertension Pregnancy 2005, 24(2):191-199.
7. Chambers J.C., Fusi L., Malik I.S., Haskard D.O., De Swiet M., Kooner J.S. Association of maternal endothelial dysfunction with preeclampsia. Am Med Assoc 2001, 285:1607-1612.
8. Roberts J.M., Lain K.Y. Recent insights into the pathogenesis of pre-eclampsia. Placenta 2002, 23(5):359-372.
9. Mikat B., Gellhaus A., Wagner N., Birdir C., Kimmig R., Köninger A. Early detection of maternal risk for preeclampsia. ISRN Obstetr Gynecol 2012, 2012.
10. Greenberg A.S., Obin M.S. Obesity and the role of adipose tissue in inflammation and metabolism. Am J Clin Nutr 2006, 83(2):461S.
11. Mehta S., Farmer J.A. Obesity and inflammation: a new look at an old problem. Curr Atherosclerosis Rep 2007, 9(2):134-138.
12. Van Dielen F.M., Van't Veer C., Schols A.M., Soeters P.B., Buurman W.A., Greve J.W. Increased leptin concentrations correlate with increased concentrations of inflammatory markers in morbidly obese individuals. Int J Obesity Relat Metabolic Disord 2001, 25(12):1759.
13. Madan J.C., Davis J.M., Craig W.Y., et al. Maternal obesity and markers of inflammation in pregnancy. Cytokine 2009, 47(1):61-64.
14. Ibrahim H.S., Omar E., Froemming G.R.A., Singh H.J. Leptin increases blood pressure and markers of endothelial activation during pregnancy in rats. BioMed Res Int 2013, 2013:6.
15. Cha J.J., Hyun Y.Y., Jee Y.H., et al. Plasma concentration of soluble intercellular adhesion molecule-1 (sICAM-1) is elevated in type 2 diabetic patients, and sICAM-1 synthesis is associated with leptin-induced activation of the mitogen-activated protein kinase (MAPK) pathway. Inflammation 2013, 1-10.
16. Izzo J.L., Sica D.A., Black H.R. Hypertension primer 2008, Lippincott Williams & Wilkins.
17. Brosnihan K.B., Neves L.A.A., Joyner J.N., et al. Enhanced renal immunocytochemical expression of ANG-(1-7) and ACE2 during pregnancy. Hypertension 2003, 42(4):749-753.
18. Neves L.A.A., Stovall K., Joyner J.N., et al. ACE2 and ANG-(1-7) in the rat uterus during early and late gestation. Am J Physiol-Regulat Integrative Comparat Physiol 2008, 294(1):R151-R161.
19. Valdes G., Neves L.A.A., Anton L., et al. Distribution of angiotensin-(1-7) and ACE2 in human placentas of normal and pathological pregnancies. Placenta 2006, 27(2-3):200-207.
20. Prada J.A.H., Ferreira A.J., Katovich M.J., et al. Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension 2008, 51(5):1312-1317.
21. Ferreira A.J., Shenoy V., Yamazato Y., et al. Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension. Am J Respir Crit Care Med 2009, 179(11):1048.
22. Fraga-Silva R.A., Sorg B.S., Wankhede M. ACE2 activation promotes antithrombotic activity. Mol Med 2010, 16(5-6):210.
23. Ferreira A.J., Shenoy V., Qi Y., et al. Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases. Exp Physiol 2011, 96(3):287-294.
24. Bella J., Kolatkar P.R., Marlor C.W., Greve J.M., Rossmann M.G. The structure of the two amino-terminal domains of human ICAM-1 suggests how it functions as a rhinovirus receptor and as an LFA-1 integrin ligand. Proc Natl Acad Sci 1998, 95(8):4140-4145.
25. Vadasz Z., Haj T., Halasz K., et al. Semaphorin 3A is a marker for disease activity and a potential immunoregulator in systemic lupus erythematosus. Arthritis Res Therapy 2012, 14(3):R146.
26. Bustin S.A., Benes V., Garson J.A., et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009, 55(4):611-622.
27. Vandesompele J., De Preter K., Pattyn F., et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002, 3(7). research0034.
28. -δδCT method. Methods 2001, 25(4):402-408.
29. Haynes W.G., Morgan D.A., Walsh S.A., Mark A.L., Sivitz W.I. Receptor-mediated regional sympathetic nerve activation by leptin. J Clin Invest 1997, 100(2):270.
30. Dunbar J.C., Hu Y., Lu H. Intracerebroventricular leptin increases lumbar and renal sympathetic nerve activity and blood pressure in normal rats. Diabetes 1997, 46(12):2040-2043.
31. Correia M.L.G., Rahmouni K. Role of leptin in the cardiovascular and endocrine complications of metabolic syndrome. Diabet Obesity Metabol 2006, 8(6):603-610.
32. Madajka M., Korda M., White J., Malinski T. Effect of aspirin on constitutive nitric oxide synthase and the biovailability of NO. Thrombosis Res 2003, 110(5):317-321.
33. Ecelbarger C.A. Proteomics and sodium transport. Proteomics Nephrol 2003, 141:124-141.
34. Bridges J.P., Gilbert J.S., Colson D., et al. Oxidative stress contributes to soluble fms-like tyrosine kinase-1 induced vascular dysfunction in pregnant rats. Am J Hypertension 2009, 22(5):564-568.
35. Murphy S.R., LaMarca B.B.D., Cockrell K., Granger J.P. Role of endothelin in mediating soluble fms-like tyrosine kinase 1-induced hypertension in pregnant rats. Hypertension 2010, 55(2):394-398.
36. Wu F.T., Stefanini M.O., Gabhann F.M., Kontos C.D., Annex B.H., Popel A.S. A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use. J Cell Mol Med 2010, 14(3):528-552.
37. Quehenberger P., Exner M., Sunder-Plassmann R., et al. Leptin induces endothelin-1 in endothelial cells in vitro. Circulat Res 2002, 90(6):711-718.
38. Schinzari F., Tesauro M., Rovella V., et al. Leptin stimulates both endothelin-1 and nitric oxide activity in lean subjects but not in patients with obesity-related metabolic syndrome. J Clin Endocrinol Metabol 2013, 98(3):1235-1241.
39. George E.M., Palei A.C., Granger J.P. Endothelin as a final common pathway in the pathophysiology of preeclampsia: therapeutic implications. Curr Opin Nephrol Hypertension 2012, 21(2):157.
40. Aggarwal P., Chandel N., Jain V., Jha V. The relationship between circulating endothelin-1, soluble fms-like tyrosine kinase-1 and soluble endoglin in preeclampsia. J Hum Hypertension 2011, 26(4):236-241.
41. Sharma D., Singh A., Trivedi S.S., Bhattacharjee J. Role of endothelin and inflammatory cytokines in pre-eclampsia - A Pilot North Indian Study. Am J Reprod Immunol 2011, 65(4):428-432.
42. Singh H.J., Rahman A., Larmie E.T., Nila A. Endothelin-1 in feto-placental tissues from normotensive pregnant women and women with pre-eclampsia. Acta Obstet Gynecol Scand 2001, 80(2):99-103.
43. Bharadwaj M.S., Strawn W.B., Groban L., et al. Angiotensin-converting enzyme 2 deficiency is associated with impaired gestational weight gain and fetal growth restriction. Hypertension 2011, 58(5):852-858.
44. Mizuiri S., Hemmi H., Arita M., et al. Expression of ACE and ACE2 in individuals with diabetic kidney disease and healthy controls. Am J Kidney Dis 2008, 51(4):613-623.
45. Liu R., Qi H., Wang J., et al. Angiotensin-converting enzyme (ACE and ACE2) imbalance correlates with the severity of cerulein-induced acute pancreatitis in mice. Exp Physiol 2014.
46. Brosnihan K., Neves L., Anton L., Joyner J., Valdes G., Merrill D. Enhanced expression of Ang-(1-7) during pregnancy. Brazilian J Med Biol Res 2004, 37(8):1255-1262.
47. Zhang H., Li Y., Zeng Y., Wu R., Ou J. Endothelin-1 downregulates angiotensin-converting enzyme-2 expression in human bronchial epithelial cells. Pharmacology 2013, 91(5-6):297-304.
48. Lambert D.W., Yarski M., Warner F.J., et al. Tumor necrosis factor-α convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J Biol Chem 2005, 280(34):30113-30119.
49. Fiorentino L., Vivanti A., Cavalera M., et al. Increased tumor necrosis factor α-converting enzyme activity induces insulin resistance and hepatosteatosis in mice. Hepatology 2010, 51(1):103-110.
50. De Caterina R., Ghiadoni L., Taddei S., et al. Soluble e-selectin in essential hypertension: a correlate of vascular structural changes&ast. Am J Hypertension 2001, 14(3):259-266.
51. Zhang M., Wang G., Wang A., Tong W., Zhang Y. Association of hypertension with coexistence of abnormal metabolism and inflammation and endothelial dysfunction. Blood Pressure 2013, 22(3):151-157.
52. Yudkin J.S., Stehouwer C., Emeis J., Coppack S. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction a potential role for cytokines originating from adipose tissue?. Arteriosclerosis Thrombosis Vascular Biol 1999, 19(4):972-978.
53. Steinberg H.O., Chaker H., Leaming R., Johnson A., Brechtel G., Baron A.D. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996, 97(11):2601.
54. Hashimoto M., Akishita M., Eto M., et al. The impairment of flow-mediated vasodilatation in obese men with visceral fat accumulation. Int J Obesity Relat Metabol Disord 1998, 22(5):477.
55. Hou N., Luo J.D. Leptin and cardiovascular diseases. Clin Exp Pharmacol Physiol 2011, 38(12):905-913.
56. Beltowski J. Leptin and atherosclerosis. Atherosclerosis 2006, 189(1):47-60.
57. Thomas M.C., Pickering R.J., Tsorotes D., et al. Genetic Ace2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE Knockout MouseNovelty and Significance. Circulat Res 2010, 107(7):888-897.
58. Wang M.Y., Yan T.Z., Newgard C.B., Unger R.H. A novel leptin receptor isoform in rat. FEBS Lett 1996, 392(2):87-90.
59. Serradeil-Le Gal C., Raufaste D., Brossard G., et al. Characterization and localization of leptin receptors in the rat kidney. FEBS Lett 1997, 404(2):185-191.
60. Han D.C., Isono M., Chen S., et al. Leptin stimulates type I collagen production in db/db mesangial cells: glucose uptake and TGF-&bgr; type II receptor expression. Kidney Int 2001, 59(4):1315-1323.
61. Wolf G., Hamann A., Han D.C., et al. Leptin stimulates proliferation and TGF-&bgr; expression in renal glomerular endothelial cells: potential role in glomerulosclerosis1. Kidney Int 1999, 56(3):860-872.
62. Kasiske B.L., Crosson J.T. Renal disease in patients with massive obesity. Archiv Internal Med 1986, 146(6):1105.
63. Sharma K., Ziyadeh F.N. The emerging role of transforming growth factor-beta in kidney diseases. Am J Physiol-Renal Physiol 1994, 266(6):F829-F842.
64. Dhaun N., Webb D.J., Kluth D.C. Endothelin-1 and the kidney-beyond BP. Br J Pharmacol 2012, 167(4):720-731.
65. Giani J.F., Burghi V., Veiras L.C., et al. Angiotensin-(1-7) attenuates diabetic nephropathy in Zucker diabetic fatty rats. Am J Physiol-Renal Physiol 2012, 302(12):F1606-F1615.
66. Oudit G.Y., Liu G.C., Zhong J., et al. Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes 2010, 59(2):529-538.
67. Dilauro M., Zimpelmann J., Robertson S.J., Genest D., Burns K.D. Effect of ACE2 and angiotensin-(1-7) in a mouse model of early chronic kidney disease. Am J Physiol-Renal Physiol 2010, 298(6):F1523-F1532.
68. Park S.E., Kim W.J., Park S.W., et al. High urinary ACE2 concentrations are associated with severity of glucose intolerance and microalbuminuria. Eur J Endocrinol 2013, 168(2):203-210.